Mircera® (methoxy polyethylene glycol-epoetin beta) – New indication
June 7, 2018 - The FDA announced the approval of Vifor’s Mircera (methoxy polyethylene glycol-epoetin beta), for the treatment of anemia associated with chronic kidney disease (CKD) in pediatric patients 5 to 17 years of age on hemodialysis (HD) who are converting from another erythropoietin stimulating agent (ESA) after their hemoglobin (Hb) level was stabilized with an ESA.
Top